Oklo vs. NuScale Power: Both Are Falling in 2026, but Only One Is Worth Buying Now

NuScale Power is the only U.S. company with an NRC-approved small modular reactor design, while Oklo has a broader customer pipeline but no NRC-certified deployable reactor until 2027 or 2028. NuScale’s market cap of $3.6 billion is roughly two-thirds below Oklo’s $11.3 billion, making it the author’s preferred speculative pick for 2026 on valuation and regulatory maturity. The article remains cautious overall because neither company has firm revenue traction yet, and both stocks have already fallen in 2026.

Analysis

The market is pricing nuclear as a single theme, but the spread between SMR and OKLO is really a spread between de-risking and optionality. SMR’s advantage is not just regulatory; it is that customers can begin underwriting a procurement process today, which matters in a capital-intensive category where financing often follows visible project milestones. That should support nearer-term multiple resilience even if absolute revenue remains modest, because investors will pay up for path certainty before they pay for scale.

OKLO’s broader customer set is a genuine second-order advantage, but it also increases execution complexity: more use cases means more bespoke contracting, site work, and regulatory permutations, which can delay the conversion from narrative to cash flow. In this tape, the harder question is not which company has the best technology, but which one can create a financing bridge from hype to first meaningful revenue without repeated equity dilution. The stock that proves it can fund deployment cheaply will likely re-rate faster than the one with the flashier customer logo slide.

The contrarian setup is that SMR may be the cleaner short-term beneficiary even if OKLO is the higher-upside long-duration story. If nuclear enthusiasm cools, names with no revenue and no approved deployable product are vulnerable to sharper multiple compression than names with a clearer regulatory asset. Conversely, any announcement of a firm customer, project financing, or partner-backed deployment would likely matter more than another generic AI-power headline; this remains a catalyst-driven trade, not a secular compounder yet.

Near term, the biggest risk is not technical failure but capital markets fatigue: if the next few quarters produce diligence-heavy MOUs rather than binding orders, both stocks can fall even if the long-term thesis remains intact. The window for sentiment reversal is likely measured in months, not days, because investors need evidence that utilities or hyperscalers will actually sign and fund. Until then, the better trade is to express conviction with defined risk rather than outright size.

Key Decisions for Investors

• Long SMR / short OKLO as a 3-6 month relative-value trade: SMR should outperform if the market rewards regulatory de-risking over pure optionality; target 15-25% spread capture, stop if OKLO announces a fully financed deployment path.
• Use call spreads instead of common stock in SMR for a 6-12 month window: the upside case is a re-rating on first binding customer milestones, but the downside is still dilution and delayed monetization.
• Avoid outright large long exposure in OKLO until there is evidence of signed, funded deployment economics; if taking exposure, keep it as a small lottery ticket with defined loss limits.
• Sell covered calls against any existing SMR position into strength over the next 1-2 quarters; implied volatility should remain elevated while the market prices milestone risk, allowing carry while reducing downside.
• Watch for a catalyst checklist: binding customer contract, project financing, NRC/regulatory progression, and partner equity commitment. If two or more land, revisit size aggressively; if not, expect narrative decay and multiple compression.